-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 17, Regeneron and CytomX Therapeutics announced a collaboration and license agreement to develop conditionally activated experimental next-generation bispecific cancer therapies
using CytomX's Probody therapeutic platform and Regeneron's Veloci-Bi bispecific antibody development platform.
Under the terms of the agreement, Regenon and CytomX will collaborate on preclinical discovery studies to identify and validate conditionally active bispecific antibodies
.
Regeneron will be responsible for funding preclinical and clinical development and commercialization activities
.
CytomX will receive $30 million upfront, future target nomination payments, up to $2 billion in research, development, regulatory and sales milestone payments, and royalties
.
The strategic focus of the collaboration is to apply CytomX's biomasking strategy to develop investigational regenerative bispecific drugs that remain inactive
until activated by proteases in the tumor microenvironment.
This technology has the potential to broaden the therapeutic window and help minimize off-target effects of these new generation of T cells involved in therapy, potentially addressing tumor types
that have historically not responded to immunotherapy.
CytomX was the first to propose ProBody technology and was named to the 2013 Fierce 15 Biotech list for the technology, followed by collaborations with Astellas, BMS and Immunogen on the technology with the following
product pipeline.
It is worth mentioning that the Safebody technology of domestic Tianyan Pharmaceutical also adopts a similar strategy and has established extensive cooperative relations
with a number of MNC.
In addition, such proantibody technology platforms include Bioatla's CAB technology (tumor immune microenvironment-dependent activation) and Sino-foreign pharmaceutical's Switch antibody technology (high-concentration ATP bridging antigens and antibodies in the tumor microenvironment).
